One study shows that docetaxel, a commonly used chemotherapeutic drug for breast cancer, can trigger the CCL3-CCR5-p38 pathway by downregulating CREB via reactive oxygen species accumulation in both breast tumor cells and macrophages, ultimately mediating tumor cell phagocytosis by macrophages (Sheng et al, 2022). Here, CREB1 is linked to neoplasm.